antidiabetic drugs
Trials Results

Albiglutide - Alogliptin - Canagliflozin - Dapagliflozin - Empagliflozin - Exenatide - Glipizide - Glyburide - Liraglutide - Lixisenatide - Metformin - Nateglinide - Pioglitazone - Rosiglitazone - Saxagliptin - Sitagliptin - Sulfonylurea - Taspoglutide - Troglitazone - Voglibose

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

albiglutide
Rosenstock (30 mg weekly), 2009albiglutide weeklyplacebo (add on MET) Exploratory SuggestingNCT00518115
alogliptin
Nauck, 2009alogliptinplacebo (add on MET) Exploratory Negative NCT00286442
dapagliflozin
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET) Exploratory - NCT00528879
exenatide
phase 2 exenatide once monthlyexenatide once monthlyweekly exenatide -
Trial 8078exenatide other dosesinsulin glargine (add on MET/SU) -
Exenatide Trial 10749exenatide before lunch and dinnerexenatide before breakfast and dinner Risk of bias -
Fineman, 2003exenatide other dosesplacebo (add on MER+/-SU) Exploratory -
Buse 10µg/d, 2004exenatide 10µg/dplacebo (add on SU)Negative NCT00039026
Buse 20µg/d, 2004exenatide 20µg/dplacebo (add on SU) -
DeFronzo 10µg/d, 2005exenatide 10µg/dplacebo (add on MET) Low risk of bias Negative NCT00039013
DeFronzo 20µg/d, 2005exenatide 20µg/dplacebo (add on MET)SuggestingNCT00039013
Heine, 2005exenatide 20µg/dinsulin (add on SU+MET)Negative
Kendall 20µg/d, 2005exenatide 20µg/dplacebo (add on SU+MET) Low risk of bias Suggesting NCT00035984
Kendall 10µg/d, 2005exenatide 10µg/dplacebo (add on SU+MET) Low risk of bias Negative NCT00035984
Kim, 2007exenatide weeklyplacebo (add on MET) Exploratory NegativeNCT00103935
Nauck, 2007exenatide 20µg/dinsulin BIAsp twice daily add on SU+MET Risk of bias Negative NCT00082407
Davis, 2007exenatide 20µg/dinsulin (add on SU/MET) Risk of bias Negative NCT00099333
Zinman 20µg/j, 2007exenatide 20µg/dplacebo (add on TZD+/-MET)Suggesting NCT00099320
Zinman 20µg/j A MODIFIER, 2007exenatide 20µg/dplacebo (add on TZD+/-MET) -
Barnett, 2007exenatide 20µg/dinsulin (add on SU/MET) Exploratory Suggesting NCT00099619
Gao, 2009exenatide 20µg/dplacebo (add on MET+/-SU) Low risk of bias Suggesting NCT00324363
Kadowaki (trial 8683), 2009exenatide 10µg/dplacebo (add on SU+/-MET/TZD) Exploratory Negative
DURATION-3 (Diamant), 2010exenatide weeklyinsulin glargine Risk of bias Suggesting NCT00641056
Buse, 2011exenatide 20µg/dplacebo (add on insulin) Low risk of bias Negative NCT00765817
glimeripide
Protocol 311glimepirideglibenclamide -
Study 202glimepirideplacebo -
Charpentier (301F)glimepiridegliclazide -
Kaneko, 1993glimepirideplacebo -
Riddle, 1994glimepirideplacebo (add on insulin) -
Draeger, 1996glimepirideglibenclamide Low risk of bias -
Dills, 1996glimepirideglyburide Exploratory -
Study 201 (Goldberg), 1996glimepirideplacebo Exploratory -
Rosenstock, 1996glimepirideplacebo -
Clark (301), 1997glimepirideglipizide -
Sonnenberg, 1997glimepiride odglimepiride bid -
Schade, 1998glimepirideplacebo -
Charpentier, 2001glimepirideplacebo (add on MET)Negative
Luis Bautista, 2003glimepirideplacebo -
Inukai, 2005glimepiridegliclazide or glibenclamide -
glipizide
Goldsteinglipizidecontrol (add on MET) -
Rosenstock, 1993glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Simonson, 1997glipizideplacebo -
Testa, 1998glipizideplacebo -
glyburide
Hermann, 1991glibenclamidec (add on MET) -
Vray, 1995glyburideplacebo -
DeFronzo, 1995glyburidec (add on MET) -
Erle, 1999glyburidec (add on MET) -
Garber, 2002glyburideplacebo -
Marre (ass), 2002glibenclamidecontrol (add on MET) -
Blonde, 2002glyburidecontrol (add on MET) -
Tosi, 2003glibenclamidecontrol (add on MET) -
Garber, 2003glyburidecontrol (add on MET) -
linagliptin
OwenslinagliptinMetformin + sulfonylurea - NCT00602472
Del Pratolinagliptinplacebo - NCT00621140
Lewin, 2010linagliptinplacebo (add on SU) - NCT00819091
Gallwitz, 2012linagliptinglimepiride (add on MET) - NCT00622284
linagliptin 1218.65 ongoing linagliptinplacebo (add on MET) - NCT01215097
linagliptin 1218.62 ongoing linagliptin low doselinagliptin - NCT01012037
linagliptin 1218.61 ongoing linagliptinplacebo (add on MET+TZD) - NCT00996658
liraglutide
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NegativeNCT00318461
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)SuggestingNCT00318461
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)Suggesting NCT00331851
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET) Risk of bias Negative NCT00331851
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SU Risk of bias Suggesting NCT00518882
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)SuggestingNCT00333151
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)SuggestingNCT00333151
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU) Low risk of bias Suggesting NCT00318422
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)SuggestingNCT00318422
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU) Low risk of bias SuggestingNCT00318422
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptin Risk of bias Suggesting NCT00700817
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptin Low risk of bias Suggesting NCT00700817
Seino, 2010liraglutide other dosesglibenclamide Low risk of bias NegativeNCT00393718
NN2211-1799 ongoing liraglutide other dosesplacebo - NCT00620282
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET) - NCT01296412
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU) - NCT00395746
EAGLE ongoing liraglutide other dosesinsulin glargine - NCT01117350
lixisenatide
GETGOAL-Llixisenatideplacebo (add on basal insulin) - NCT00715624
Ratner DRI6012, 2010lixisenatideplacebo (add on MET) Exploratory - NCT00299871
GETGOAL-M ongoing lixisenatideplacebo (add on MET) - NCT00712673
GetGoal-M-As ongoing lixisenatideplacebo (add on MET+/-SU) - NCT01169779
GetGoal Duo1 ongoing lixisenatideplacebo (add on basal insulin) - NCT00975286
GETGOAL-S ongoing lixisenatideplacebo (add on SU+/-MET) - NCT00713830
GETGOAL-P ongoing lixisenatideplacebo (add on TZD+/-MET) - NCT00763815
GETGOAL-L-ASIA ongoing lixisenatideplacebo (add on basal insulin) - NCT00866658
EFC10780, 2010 ongoing lixisenatidesitagliptin (add on MET) - NCT00976937
mitiglinide
Gaomitiglinidenateglinide - NCT00461617
Kumashiro, 2007mitiglinideon top insulin glargine -
Kaku, 2009mitiglinideplacebo (on top pioglitazone) -
nateglinide
Hanefeld, 1990nateglinideplacebo -
Goldberg, 1998repaglinideplacebo -
Horton, 2000nateglinideplacebo -
Jovanovic, 2000repaglinideplacebo -
Moses, 2001nateglinideplacebo -
Marre, 2002nateglinideplacebo Exploratory -
Saloranta, 2002nateglinideplacebo -
Bech, 2003repaglinideplacebo -
Mari, 2005nateglinideplacebo -
Ristic, 2006nateglinidegliclazide (add on MET) Exploratory -
Li, 2007nategliniderepaglinide -
Li, 2009nategliniderepaglinide -
pioglitazone
PNFP-014pioglitazone + insulinplacebo (add on insulin) Exploratory Negative
OPI-502pioglitazone + insulinplacebo (add on insulin) Exploratory Negative
linagliptin 1264.3 ongoing linagliptin + pioglitazonepioglitazone - NCT01183013
repaglinide
Goldberg, 1998repaglinideplacebo Exploratory -
Moses, 1999repaglinidecontrol (add on MET) Exploratory -
Chuang, 1999repaglinideplacebo -
Landgraf, 1999repaglinideglibenclamide -
Marbury, 1999repaglinideglibenclamide -
Wolffenbuttel, 1999repaglinideglibenclamide -
Landin-Olsson, 1999repaglinideplacebo (on top bedtime NPH-insulin) -
Raskin, 2000repaglinideon top troglitazone -
Jovanovic, 2000repaglinideplacebo -
Madsbad, 2001repaglinideglipizide -
Raskin, 2001repaglinideon top rosiglitazone -
Raskin, 2001repaglinideon top pioglitazone -
Lund, 2007repaglinidemetformin -
rosiglitazone
BRL 49653/347 rosiglitazoneplacebo (add on insulin) Exploratory - NCT00054782
49653/085 rosiglitazoneplacebo (add on insulin) Exploratory -
49653/095 rosiglitazoneplacebo (add on insulin) Exploratory -
49653/136 rosiglitazoneplacebo Exploratory -
SB-712753/009 rosiglitazone Exploratory -
saxagliptin
saxagliptin vs sitagliptinsaxagliptinsitagliptin (add on MET) -
CV181-080saxagliptinplacebo (add on MET) - NCT00885378
CV181-066saxagliptinplacebo (add on MET) - NCT00683657
Hollandersaxagliptinplacebo (add on TZD) - NCT00295633
CV181-057saxagliptinplacebo (add on insulin) - NCT00757588
saxgliptin, renal studysaxagliptinplacebo (add on current treatment) -
CV181-011saxagliptinplacebo (monotherapy) - NCT00121641
CV181-038saxagliptinplacebo (monotherapy) - NCT00316082
CV181-041saxagliptinplacebo (monotherapy) - NCT00374907
Rosenstock, 2008saxagliptinplacebo (monotherapy) - NCT00950599
DeFronzo, 2009saxagliptinplacebo (add on MET)Negative NCT00121667
Jadzinsky, 2009saxagliptinplacebo (add on MET) - NCT00327015
sitagliptin
Charbonnel, 2006sitagliptinplacebo (add on MET)NegativeNCT0086515
Rosenstock (sit on top pio vs pbo), 2006sitagliptinplacebo (on top PIO)SuggestingNCT00086502
Nauck, 2007sitagliptinplacebo (add on MET)NegativeNCT00094770
Scott** (sit vs pbo on top met), 2007sitagliptinplacebo (add on MET)Negative
Hermansen, 2007sitagliptinplacebo (on-top glimepiride+/- metformine)Negative
taspoglutide
Nauck 10 once weekly vs PBO, 2009taspoglutide 10mg once weeklyplacebo Exploratory SuggestingNCT00423501
Ratner (20mg once weekly), 2010taspoglutideplacebo (add on MET) Exploratory SuggestingNCT00460941
BC22092 ongoing taspoglutideplacebo (add on MET) - NCT00823992
BC21713 (vs placebo) ongoing taspoglutideplacebo - NCT00754988
BC21893 ongoing taspoglutidepioglitazone - NCT00909597
ZC22565 ongoing taspoglutideinsulin glargine - NCT01051011
BC20965 ongoing taspoglutideinsulin glargine (add on MET) - NCT00755287
BC21625 ongoing taspoglutideexenatide - NCT00717457
BC20963 ongoing taspoglutideplacebo - NCT00744367
vildagliptin
Ahren, 2004vildagliptinplacebo (add on MET)Negative
Bosi, 2007vildagliptinplacebo (add on MET)NegativeNCT00099892
Fonseca, 2007vildagliptinplacebo (add on insulin)SuggestingNCT00099931
Garber, 2007vildagliptinplacebo (on top pioglitazone)NegativeNCT00099853
Rosenstock** (vilda + pio vs pio), 2007vildagliptinplacebo (add on TZD)NegativeNCT00101803
Bolli, 2008vildagliptinpioglitazone (add on MET)NegativeNCT00237237
Ferrannini, 2009vildagliptinSulfonylurea (add on to MET) Exploratory SuggestingNCT00106340
Goodman, 2009vildagliptinplacebo (add on MET) Exploratory Negative



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons